Formulation and Optimization of Oro dispersible Tablet of Pentoprazole Sodium as Proton Pump Inhibitor

被引:0
|
作者
Modi, Jaimin [1 ]
Kamble, R. K. [1 ]
Chauhan, Chetan Singh [1 ]
机构
[1] Bhupal Nobles Coll Pharm, Dept Ind Pharm, Udaipur, Rajasthan, India
来源
INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH AND ALLIED SCIENCES | 2013年 / 2卷 / 03期
关键词
Orodispersible; Pantoprazole sodium; Crosspovidone; Sodium starch glycolate;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In the present study, the aim was to formulate and optimize an orodispersible formulation of pantoprazole sodium using a combination of superdisintegrants. cThe tablets were made by direct compression technique with superdisintegrants i.e. crosspovidone and sodium starch glycolate incorporated in it. Differential Scanning Calorimetry (DSC) studies exhibited physiochemical compatibility between pantoprazole sodium and various excipients used in the tablet formulation. In an attempt to construct a statistical model for the prediction of disintegration time and percentage friability, a 32 randomized full and reduced factorial design was used to optimize the influence of theamounts of superdisintegrants. Amount of crosspovidone and sodium starch glycolate were taken as independent variables and disintegration time and fribility as dependent responses. Concerning the optimization study, the multiple regression analysis revealed that an optimum concentration of crosspovidone and a higher percentage of sodium starch glycolate are required for obtaining rapidly disintegrating tablets with adequate friability and mechanical strength. A checkpoint batch was also prepared to prove the validity of the evolved mathematical modelStability studies carried out as per ICH Q1 A guidelines suggested the stable formulations for the tested time period of 3 months accelerated study. In conclusion, this investigation demonstrated the potential of experimental design in understanding the effect of the formulation variables on the quality of mouth dissolve tablets.
引用
收藏
页码:38 / 49
页数:12
相关论文
共 50 条
  • [21] Acid Control Cannot Be Improved with a Modified-Release Formulation of a Proton Pump Inhibitor Compared with Twice-Daily Dosing of the Conventional Formulation
    Rohss, Kerstin
    Wilder-Smith, Clive
    Bokelund-Singh, Sara
    Sagar, Mohamed
    Nagy, Peter
    DIGESTIVE DISEASES AND SCIENCES, 2010, 55 (12) : 3423 - 3429
  • [22] Evaluation of the effect of new formulation, food, or a proton pump inhibitor on the relative bioavailability of the smoothened inhibitor glasdegib (PF-04449913) in healthy volunteers
    Nagdeep Giri
    Lisa H. Lam
    Robert R. LaBadie
    Joseph F. Krzyzaniak
    Hong Jiang
    Brian Hee
    Yali Liang
    M. Naveed Shaik
    Cancer Chemotherapy and Pharmacology, 2017, 80 : 1249 - 1260
  • [23] Evaluation of the effect of new formulation, food, or a proton pump inhibitor on the relative bioavailability of the smoothened inhibitor glasdegib (PF-04449913) in healthy volunteers
    Giri, Nagdeep
    Lam, Lisa H.
    LaBadie, Robert R.
    Krzyzaniak, Joseph F.
    Jiang, Hong
    Hee, Brian
    Liang, Yali
    Shaik, M. Naveed
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 80 (06) : 1249 - 1260
  • [24] Proton pump inhibitor administration via nasogastric tube in pediatric practice: Comparative analysis with protocol optimization
    Ponrouch, M. P.
    Sautou-Miranda, V.
    Boyer, A.
    Bourdeaux, D.
    Montagner, A.
    Chopineau, J.
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2010, 390 (02) : 160 - 164
  • [25] Gastric Biopsy Results From Patients Treated With Dexlansoprazole MR, a Proton Pump Inhibitor with a Dual Delayed Release Formulation
    Bronner, Mary
    Perez, M. Claudia
    Dabholkar, Aruna
    Palo, William
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2009, 104 : S5 - S5
  • [26] Radiation lethality potentiation in total body irradiated mice by a commonly prescribed proton pump inhibitor, Pantoprazole sodium
    Biju, Prabath G.
    Gubrij, Igor
    Garg, Sarita
    Gupta, Prem K.
    Hauer-Jensen, Martin
    Burnett, Alexander F.
    INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, 2014, 90 (07) : 554 - 559
  • [27] EFFECTS OF PANCREATIC DIGESTIVE ENZYMES, SODIUM-BICARBONATE, AND A PROTON PUMP INHIBITOR ON STEATORRHEA CAUSED BY PANCREATIC DISEASES
    NAKAMURA, T
    TAKEBE, K
    KUDOH, K
    ISHII, M
    IMAMURA, K
    KIKUCHI, H
    KASAI, F
    TANDOH, Y
    YAMADA, N
    ARAI, Y
    TERADA, A
    MACHIDA, K
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 1995, 23 (01) : 37 - 47
  • [28] Effects of Dexlansoprazole MR, a Novel Dual Delayed Release Formulation of a Proton Pump Inhibitor, on Plasma Gastrin Levels in Healthy Subjects
    Zhang, Weijiang
    Wu, Jingtao
    Atkinson, Stuart N.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 49 (04): : 444 - 454
  • [29] Lack of Electrocardiographic Effect of Dexlansoprazole MR, a Novel Modified-Release Formulation of the Proton Pump Inhibitor Dexlansoprazole, in Healthy Participants
    Vakily, Majid
    Wu, Jingtao
    Atkinson, Stuart N.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 49 (12): : 1447 - 1455
  • [30] Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience
    Peura, D. A.
    Metz, D. C.
    Dabholkar, A. H.
    Paris, M. M.
    Yu, P.
    Atkinson, S. N.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2009, 30 (10) : 1010 - 1021